Table 1.
The statuses of related gene mutations* and IC50 values (μM)** of chidamide, crizotinib for 13 NSCLC cell lines with or without chidamide co-treatment
| Cell line | ALK mutation | ROS1 mutation |
EGFR mutation |
K-RAS mutation | c-MET amplif. | chidamide IC50 (A) | crizotinib IC50 (B) | crizotinib IC50*** (C) | IC50 Fold change (C to B) | t-test, p-value(B vs. C) |
|---|---|---|---|---|---|---|---|---|---|---|
| EBC-1 | free | free | free | free | positive | 1.24±0.37 | 0.004±0.00 | 0.003±0.00 | 0.75±0.10 | 0.011 |
| HCC827 | free | free | positive | free | free | 0.90±0.08 | 0.93±0.21 | 0.49±0.09 | 0.54±0.07 | 0.007 |
| H661 | free | free | free | free | free | 5.51±0.77 | 1.10±0.45 | 0.62±0.22 | 0.58±0.06 | 0.006 |
| Calu-3 | free | free | free | free | free | 0.79±0.10 | 4.22±2.22 | 1.98±1.42 | 0.44±0.08 | 0.007 |
| H1299 | free | free | free | free | free | 4.09±0.16 | 1.34±0.13 | 1.10±0.17 | 0.82±0.05 | 0.026 |
| H358 | free | free | free | positive | free | 1.73±0.32 | 1.46±0.61 | 1.13±0.41 | 0.79±0.07 | 0.041 |
| H596 | free | free | free | free | free | 12.6±0.05 | 4.98±1.56 | 4.03±0.92 | 0.81±0.07 | 0.044 |
| H460 | free | free | free | positive | free | 5.99±0.65 | 1.84±0.26 | 1.59±0.23 | 0.86±0.00 | 0.001 |
| A549 | free | free | free | positive | free | 8.25±1.41 | 3.21±1.51 | 3.50±1.37 | 1.11±0.09 | 0.166 |
| H1975 | free | free | positive | free | free | 1.85±0.06 | 1.86±0.66 | 1.94±0.88 | 1.03±0.11 | 0.706 |
| H1650 | free | free | positive | free | free | 92.5±15.7 | 2.17±0.57 | 2.25±0.61 | 1.03±0.03 | 0.166 |
| H292 | free | free | free | free | free | 5.46±0.30 | 1.24±0.11 | 1.66±0.28 | 1.33±0.13 | 0.048 |
| H1395 | free | free | free | free | free | 1.05±0.01 | 4.91±2.29 | 4.85±2.26 | 0.99±0.01 | 0.140 |
*According to CCLE databases 27; **Mean ± SD; ***Cotreated with chidamide at 1/4 IC50.